Salk vaccine

Salk vaccine. The Salk vaccine, formally known as inactivated poliovirus vaccine (IPV), is a vaccine against poliomyelitis developed by American medical researcher Jonas Salk and his team at the University of Pittsburgh. Its introduction in 1955 marked a pivotal moment in 20th-century medicine, dramatically reducing the incidence of paralytic polio worldwide. The vaccine's development was a massive scientific and logistical undertaking, heavily supported by the National Foundation for Infantile Paralysis and its public fundraising campaigns, most famously the March of Dimes.

History and development

The urgent quest for a polio vaccine intensified in the post-war era, as epidemics of the disease caused widespread fear and paralysis, particularly among children. Building on foundational work by scientists like John Enders, Thomas Weller, and Frederick Robbins, who successfully cultivated the poliovirus in non-neural tissue, Jonas Salk pursued a killed-virus approach. His research was conducted primarily at the University of Pittsburgh with crucial support from the National Foundation for Infantile Paralysis, then led by Basil O'Connor. Key to the process was the use of the Wistar Institute's stable cell lines and the virulent Mahoney strain of poliovirus. Salk's methodology involved inactivating the virus with formalin, a technique informed by earlier vaccine work on influenza and Japanese encephalitis.

Clinical trials and approval

The unprecedented scale of the vaccine's field trial, organized in 1954 by the National Foundation for Infantile Paralysis and overseen by the University of Michigan's Thomas Francis Jr., involved nearly two million American schoolchildren, making it one of the largest clinical experiments in history. The successful results, announced at a press conference at the University of Michigan on April 12, 1955, led to rapid licensing by the United States government's Laboratory of Biologics Control. This moment, hailed as a victory, was soon marred by the Cutter incident, where improperly inactivated vaccine from Cutter Laboratories caused cases of paralytic polio, leading to enhanced federal regulatory oversight by the Division of Biologics Standards.

Manufacturing and composition

The original vaccine was a trivalent preparation, containing inactivated strains of all three serotypes of poliovirus: Mahoney (type 1), MEF-1 (type 2), and Saukett (type 3). Manufacturing involved growing the virus in cultures of monkey kidney tissue, such as from rhesus macaques, followed by purification and inactivation using formalin. Major pharmaceutical firms, including Connaught Laboratories, Parke-Davis, and Eli Lilly and Company, were contracted for large-scale production. Modern IPV, as recommended by the World Health Organization, often uses attenuated strains for production but remains an inactivated, injectable formulation, distinct from the oral Sabin vaccine developed later by Albert Sabin.

Administration and schedule

The vaccine is administered via intramuscular injection, typically into the deltoid muscle of the upper arm or the anterolateral thigh in infants. The standard immunization schedule, as defined by bodies like the Advisory Committee on Immunization Practices and the Centers for Disease Control and Prevention, involves a primary series of four doses, given at ages 2 months, 4 months, 6–18 months, and a booster between 4–6 years. In many countries, including the United States, it is part of a combination vaccine, such as DTaP-IPV-Hib, which also protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b.

Impact and legacy

The introduction of the Salk vaccine had an immediate and profound impact, reducing reported cases of paralytic polio in the United States from over 28,000 in 1955 to fewer than 2,000 by 1960. It paved the way for global eradication efforts led by the World Health Organization and partners like UNICEF and the Rotary International. While largely supplanted by the oral Sabin vaccine in global campaigns due to its advantages in herd immunity and ease of administration, IPV has seen a resurgence in routine immunization in polio-free regions to eliminate vaccine-associated paralytic polio. The vaccine stands as a landmark achievement in public health, symbolizing the power of organized scientific research and mass vaccination.

Category:Vaccines Category:Polio